Skip to main content
Caplight Logo









CellProthera

CellProthera

Private
MulhouseHealthcare & Life Scienceshttps://www.cellprothera.com/en/home/

Last Round

VC Round

Mar 30, 2023

Total Funding Raised

$22.64M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

CellProthera is a biotechnology company that develops regenerative cell therapy for the structural and functional regeneration of cardiac lesions following a severe heart attack.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware + Subscription, Government Contracts, Hardware Sales

AI Layer

Non-AI

Keywords

regenerative cell therapyautologous cell therapycardiac cell therapyheart attack therapystem cell therapyautomated cell expansioncardiac regenerationclinical stage biotechCD34+ stem cellsheart failure therapyrazor and blade modelcell therapy manufacturingacute myocardial infarctionAMIbiotech equipment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CellProthera Comparables

Compare CellProthera with similar companies based on industry and business-model similarity.

CellProthera comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BioCardia Inc
81%
Bayer AG
73%
Vericel Corporation
68%

CellProthera Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMar 30, 2023
GrantMay 1, 2018
VC RoundSep 3, 2014
GrantJul 11, 2013
SeedSep 1, 2009

Key People

Founding team and executive leadership

Olivier Friedrich

Directeur Adm. & Financier - CFO DRH

Executive Team

Jean-Olivier HIRSCH

Chief Operating Officer, Quality And Regulatory Aff. Director - Qualified Person

Executive Team

CellProthera Investors

Notable investors and investment history

CellProthera investors
InvestorRounds
European Union's Horizon Research and Innovation programGrant
Alsace Business AngelsVC Round, Seed
SODIVVC Round
BpifranceVC Round, Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 61% MoM, reaching 1K.

  • Jul 20, 2026

    Open roles increased to 29, 107% of current headcount.

CellProthera Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CellProthera Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CellProthera's valuation, stock price, and market status.

Firmographic Details

HeadquartersMulhouse
Employee Range23
Year Founded2008
Last FundingMar 30, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?